Abstract：
UNASSIGNED: Hyperkalemia is an electrolyte abnormality with potentially life-threatening consequences. Published data have shown that potassium-binding polymer patiromer (Veltassa) is associated with reduced rates of severe edema and hospitalization for heart failure compared with sodium zirconium cyclosilicate (SZC, Lokelma) when treating hyperkalemia. The aim of this study was to evaluate the possible costs associated with these interventions in the Spanish and UK settings.
UNASSIGNED: A cost-analysis model was developed in Microsoft Excel to compare the costs associated with patiromer and SZC for the management of hyperkalemia. Clinical event rates were taken from a published real-world comparative study, with the base case capturing the statistically significant reduction in severe edema with patiromer vs SZC and a sensitivity analysis also including the non-statistically significant reduction in hospitalization for heart failure. Country-specific costs, expressed in 2022 Euros (EUR) and British pounds sterling (GBP), were evaluated from a healthcare payer perspective and included pharmacy costs and costs of clinical events.
UNASSIGNED: Patiromer may be associated with cost savings of EUR 107 and GBP 630 per patient-year of treatment vs SZC in Spain and the UK, respectively. The majority of cost savings were due to the possible lower daily cost of patiromer compared with SZC. Including the difference in heart failure hospitalization rates in a sensitivity analysis led to greater cost savings with patiromer over SZC, increasing to EUR 460 and GBP 902 in Spain and the UK, respectively. Extrapolation of patient-level economic outcomes to a population level found that patiromer was associated with annual cost savings of EUR 30.6 million in Spain, and GBP 801.7 million in the UK vs SZC.
UNASSIGNED: Patiromer has the potential to be cost saving vs SZC for the treatment of hyperkalemia in Spain and the UK based on the results of a real-world evidence analysis.
UNASSIGNED: A cost-analysis model was developed in Microsoft Excel to compare the costs associated with patiromer and SZC for the management of hyperkalemia. Clinical event rates were taken from a published real-world comparative study, with the base case capturing the statistically significant reduction in severe edema with patiromer vs SZC and a sensitivity analysis also including the non-statistically significant reduction in hospitalization for heart failure. Country-specific costs, expressed in 2022 Euros (EUR) and British pounds sterling (GBP), were evaluated from a healthcare payer perspective and included pharmacy costs and costs of clinical events.
UNASSIGNED: Patiromer may be associated with cost savings of EUR 107 and GBP 630 per patient-year of treatment vs SZC in Spain and the UK, respectively. The majority of cost savings were due to the possible lower daily cost of patiromer compared with SZC. Including the difference in heart failure hospitalization rates in a sensitivity analysis led to greater cost savings with patiromer over SZC, increasing to EUR 460 and GBP 902 in Spain and the UK, respectively. Extrapolation of patient-level economic outcomes to a population level found that patiromer was associated with annual cost savings of EUR 30.6 million in Spain, and GBP 801.7 million in the UK vs SZC.
UNASSIGNED: Patiromer has the potential to be cost saving vs SZC for the treatment of hyperkalemia in Spain and the UK based on the results of a real-world evidence analysis.
摘要：
■高钾血症是一种电解质异常，可能危及生命。已发表的数据表明，与环硅酸锆钠相比，钾结合聚合物patiromer（Veltassa）与严重水肿和心力衰竭住院率降低有关（SZC，Lokelma）治疗高钾血症时。这项研究的目的是评估在西班牙和英国环境中与这些干预措施相关的可能成本。
■在MicrosoftExcel中开发了成本分析模型，以比较与patiromer和SZC相关的用于管理高钾血症的成本。临床事件发生率来自一项已发表的真实世界比较研究，在基本病例中，Patiromer与SZC相比，严重水肿在统计学上显着降低，敏感性分析还包括心力衰竭住院率的非统计学显着降低。特定国家的费用，以2022年英镑(GBP)和欧元(EUR)表示，从医疗保健支付者的角度进行评估，并包括药房费用和临床事件的费用。
■Patiromer与西班牙和英国的SZC相比，每患者年的治疗成本可节省107欧元和630英镑，分别。与SZC相比，大多数成本节省是由于patiromer的每日成本可能较低。在敏感性分析中包括心力衰竭住院率的差异，从而比SZC节省了更多的成本，在西班牙和英国增加到460欧元和902英镑，分别。将患者水平的经济结果推断为人口水平发现，在西班牙，Patiromer每年可节省3060万欧元的成本。英国和SZC的8.017亿英镑。
■根据实际证据分析的结果，在西班牙和英国，与SZC相比，Patiromer具有节省成本的潜力。
■在MicrosoftExcel中开发了成本分析模型，以比较与patiromer和SZC相关的用于管理高钾血症的成本。临床事件发生率来自一项已发表的真实世界比较研究，在基本病例中，Patiromer与SZC相比，严重水肿在统计学上显着降低，敏感性分析还包括心力衰竭住院率的非统计学显着降低。特定国家的费用，以2022年英镑(GBP)和欧元(EUR)表示，从医疗保健支付者的角度进行评估，并包括药房费用和临床事件的费用。
■Patiromer与西班牙和英国的SZC相比，每患者年的治疗成本可节省107欧元和630英镑，分别。与SZC相比，大多数成本节省是由于patiromer的每日成本可能较低。在敏感性分析中包括心力衰竭住院率的差异，从而比SZC节省了更多的成本，在西班牙和英国增加到460欧元和902英镑，分别。将患者水平的经济结果推断为人口水平发现，在西班牙，Patiromer每年可节省3060万欧元的成本。英国和SZC的8.017亿英镑。
■根据实际证据分析的结果，在西班牙和英国，与SZC相比，Patiromer具有节省成本的潜力。
